drugset / Trial / NCT00600808

Sustained Release Formulation of Somatropin (rDNA Origin)for Injection

NCT00600808

Phase 2/3 Completed 51 enrolled BioPartners GmbH LG Life Sciences · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

Annualised height velocity after 12/24 months treatment and HV SDS height velocity after 12/24 months treatment expressed as number of standard deviations difference from the mean population height velocity for the appropriate gender and chronological age.

Timeline

Start
2003-06
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic Other

Indications